A recently conducted survey has found that only 50% of parents who tried acquiring mental health services for their children during the coronavirus pandemic were successful in their attempts. The survey was carried out in September 2021 by DotCom Therapy, a pediatric teletherapy provider.
The objective of the survey was to measure the effect of the pandemic on mental health in children, as well as how children were impacted by going back to physical classes after a year of online learning and the coronavirus lockdown. The survey collected responses from more than 1,000 guardians and parents in the United States who had one or more children aged below 18. Its findings highlighted the disconnect in the mental healthcare system and the effect this has on the mental health of children. Respondents reported that the largest barrier to acquiring mental healthcare for their children was lack of resources and access.
Of the total number of respondents, almost 80% stated that they believed the healthcare and educational systems needed to offer more and better mental health support for kids while 61% stated that they didn’t know the complete extent of mental health services their school systems provided. Almost 40% of respondents stated that there was a lack of resources to help them find the right therapist for their children while another 38% stated that not having enough therapists was a barrier to sufficient mental health services.
In addition to this, a one-third of parents admitted to not trying to access mental health services for their children, even after becoming aware of their children’s mental issues, including panic attacks, general and social anxiety. The survey also found that most parents were receptive to pediatric therapy.
In a press release, DotCom Therapy president Rachel Mack Robinson stated that while parents wanted to help their children, most were overwhelmed and didn’t know where to begin, as mental health resources had decreased across healthcare and educational institutions. Robinson added that pediatric teletherapy could help because it offered an effective and immediate solution to the therapist crisis, while also offering resources and support to clinics, hospitals and schools.
The findings of this survey are significant, as the total impact of the coronavirus pandemic on the youth hasn’t even peaked yet. Figures from the CDC show that every one in five children has an emotional, behavioral or mental disorder. However, only 20% of this number is receiving treatment from a mental health provider. Hopefully, the number of patients benefiting from psychiatric treatment will increase once the novel formulations being developed by companies like Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) hit the market.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
